Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

Company Overview - Arcutis Biotherapeutics, Inc. (ARQT) is part of the Medical group, which consists of 979 companies and is currently ranked 8 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 489 stocks and is ranked 147 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, Arcutis Biotherapeutics has gained approximately 6%, while the average return for Medical companies is -7.4%, indicating that ARQT is outperforming its peers [4] - The Zacks Consensus Estimate for ARQT's full-year earnings has increased by 25.7% over the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4] Zacks Rank - Arcutis Biotherapeutics currently holds a Zacks Rank of 2 (Buy), which emphasizes its potential for improving earnings outlooks [3] - In comparison, another Medical stock, Tenet Healthcare (THC), has a Zacks Rank of 1 (Strong Buy) and has returned 31.2% year-to-date [5]